Bayer

(IN BRIEF) Bayer is making a significant investment of EUR 220 million in research and development (R&D) at its Monheim site in Germany, focusing on its Crop Protection business. This represents the company’s largest single investment in Crop Protection in … Read the full press release →

(IN BRIEF) Pairwise and Bayer have entered into a new five-year, multi-million Dollar collaboration focusing on gene-edited short-stature corn. Building on their initial partnership for corn, soy, wheat, cotton, and canola, this collaboration aims to optimize and enhance gene-edited short-stature … Read the full press release →

(IN BRIEF) BlueRock Therapeutics and bit.bio have announced a collaboration and option agreement to discover and manufacture iPSC-derived regulatory T cells (Tregs) for therapeutic use. Tregs are crucial for immune system balance and controlling excessive immune reactions, making them potential … Read the full press release →

(IN BRIEF) Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company owned by Bayer AG, has begun the Phase 1/Phase 2 LION-CS101 clinical trial for patients with limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). The trial is evaluating AB-1003 (LION-101), an investigational … Read the full press release →

(IN BRIEF) A scientific statement published in the European Journal of Preventive Cardiology highlights that childhood obesity is a critical factor leading to cardiovascular disease (CVD) in adulthood. Childhood obesity is on the rise globally, and the associated problems of … Read the full press release →

Not intended for U.S. and UK Media (IN BRIEF) Bayer AG has partnered with Acuitas Therapeutics, Inc. to enhance its gene therapy portfolio. Acuitas’ lipid nanoparticle (LNP) delivery technology will enable targeted and efficient delivery of gene editing RNA components … Read the full press release →

Not intended UK Media (IN BRIEF) Bayer and Cedilla Therapeutics have entered into an exclusive license agreement to develop and commercialize Cedilla’s CyclinE1/CDK2 complex inhibitors for precision oncology. These inhibitors target oncogenic drivers and offer a unique method of action, … Read the full press release →

(IN BRIEF) Bayer has announced the recipients of its 2023 Grants4Ag program, which will provide funding and mentorship to researchers working on sustainability and biotechnology in agriculture. The program will award grants ranging from €5,000 to €15,000 and connect researchers … Read the full press release →

(NOTIZIA IN BREVE) Bayer, la società di scienze della vita, ha annunciato un investimento di 60 milioni di euro nel suo impianto di produzione di semi di mais a Pochuiky, in Ucraina, per rafforzare la sua attività di Crop Science … Read the full press release →

(IN BRIEF) Bayer, the life sciences company, has announced a €60 million investment in its corn seed production facility in Pochuiky, Ukraine, to strengthen its Crop Science business and contribute to rebuilding the economy of the country. The investment includes … Read the full press release →

(IN BRIEF) Siemens has supplied Bayer’s Crop Science Division with pressure transmitters containing standardized ID links, enabling the transfer of digital documentation in real time to the ERP system used by the customer. The transmitters feature technology that complies with … Read the full press release →